The burden of disease and economic impact of sugar-sweetened beverages' consumption in Argentina: A modeling study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
02
2022
accepted:
19
12
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Approximately two-thirds of Argentine adults are overweight or obese, and 11% have diabetes. Over the last two decades, all population groups have increased their consumption of ultra-processed foods and sugar-sweetened beverages (SSB). We aimed to estimate the disease burden-deaths, events, and costs to the health system-attributed to SSB consumption in Argentina. We used a comparative risk assessment framework to estimate the health and economic impacts that would be avoided in a scenario without sugar-sweetened beverage (SSB) consumption. We calculated the direct effects on diabetes, cardiovascular disease, and BMI, and then estimated the effects of BMI on disease incidence. Finally, we applied the population attributable factor to calculate the health and economic burden avoided in Argentina in 2020. Our model estimated that about 4,425 deaths, 110,000 healthy life years lost to premature death and disability, more than 520,000 cases of overweight and obesity in adults, and 774,000 in children and adolescents would be attributed to SSB Consumption in Argentina. This disease burden corresponds to 23% of type-2 diabetes cases and other significant proportions of cardiovascular disease and cancer. The overweight and obesity costs attributable to SSB totaled approximately $47 million in adults and $15 million in children and adolescents. A significant number of disease cases, deaths, and health care costs could be attributed to SSB consumption in Argentina. Implementing measures to reduce the sugar content in beverages is a pending debt for the country and could lead to measurable improvements in population health, especially among children and adolescents.
Sections du résumé
BACKGROUND
Approximately two-thirds of Argentine adults are overweight or obese, and 11% have diabetes. Over the last two decades, all population groups have increased their consumption of ultra-processed foods and sugar-sweetened beverages (SSB). We aimed to estimate the disease burden-deaths, events, and costs to the health system-attributed to SSB consumption in Argentina.
METHODS
We used a comparative risk assessment framework to estimate the health and economic impacts that would be avoided in a scenario without sugar-sweetened beverage (SSB) consumption. We calculated the direct effects on diabetes, cardiovascular disease, and BMI, and then estimated the effects of BMI on disease incidence. Finally, we applied the population attributable factor to calculate the health and economic burden avoided in Argentina in 2020.
RESULTS
Our model estimated that about 4,425 deaths, 110,000 healthy life years lost to premature death and disability, more than 520,000 cases of overweight and obesity in adults, and 774,000 in children and adolescents would be attributed to SSB Consumption in Argentina. This disease burden corresponds to 23% of type-2 diabetes cases and other significant proportions of cardiovascular disease and cancer. The overweight and obesity costs attributable to SSB totaled approximately $47 million in adults and $15 million in children and adolescents.
CONCLUSION
A significant number of disease cases, deaths, and health care costs could be attributed to SSB consumption in Argentina. Implementing measures to reduce the sugar content in beverages is a pending debt for the country and could lead to measurable improvements in population health, especially among children and adolescents.
Identifiants
pubmed: 36821592
doi: 10.1371/journal.pone.0279978
pii: PONE-D-22-04375
pmc: PMC9949658
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0279978Informations de copyright
Copyright: © 2023 Bardach et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMJ Glob Health. 2018 Feb 19;3(1):e000535
pubmed: 29527342
Circulation. 2015 Aug 25;132(8):639-66
pubmed: 26124185
BMJ Glob Health. 2021 Oct;6(10):
pubmed: 34737167
BMJ Glob Health. 2020 Feb 11;5(2):e002040
pubmed: 32133191
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
PLoS Med. 2018 Jul 3;15(7):e1002597
pubmed: 29969444
Am J Public Health. 2012 Jan;102(1):178-83
pubmed: 22095333
N Engl J Med. 2012 Oct 11;367(15):1407-16
pubmed: 22998339
Am J Prev Med. 2021 Feb;60(2):276-284
pubmed: 33349472
BMC Public Health. 2021 Jul 27;21(1):1460
pubmed: 34315428
Nutrients. 2018 Mar 22;10(4):
pubmed: 29565308
PLoS One. 2017 May 17;12(5):e0176336
pubmed: 28520716
Lancet Diabetes Endocrinol. 2014 Apr;2(4):321-332
pubmed: 24703050
N Engl J Med. 2012 Oct 11;367(15):1397-406
pubmed: 22998340
Br J Sports Med. 2016 Apr;50(8):496-504
pubmed: 27044603
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Am J Clin Nutr. 2009 May;89(5):1299-306
pubmed: 19339405
J Am Heart Assoc. 2020 May 18;9(10):e014883
pubmed: 32397792
Popul Health Metr. 2003 Apr 14;1(1):4
pubmed: 12773212
Adv Nutr. 2021 Feb 1;12(1):89-101
pubmed: 32696948
PLoS Med. 2018 Oct 5;15(10):e1002664
pubmed: 30289898
Nat Rev Endocrinol. 2022 Apr;18(4):205-218
pubmed: 35064240
PLoS Med. 2020 Jul 28;17(7):e1003224
pubmed: 32722677
PLoS Med. 2020 Jul 28;17(7):e1003221
pubmed: 32722682
PLoS Med. 2020 Feb 11;17(2):e1003015
pubmed: 32045424
Child Obes. 2015 Aug;11(4):338-46
pubmed: 26258560